Cocrystal Pharma Inc (COCP)

[mick]

GOOD MESSAGE;'Cocrystal Pharma Inc. (COCP)'

Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants
Jun. 14, 2021 9:15 AM ETCocrystal Pharma, Inc. (COCP)By: Mamta Mayani, SA News Editor
Cocrystal Pharma (NASDAQ:COCP) jumps 11.2% premarket after announcing that its protease inhibitor CDI-45205 is active against SARS-CoV-2 and two variants.
Two reference inhibitors including remdesivir and PF-00835231 were included in the study as comparators.
Results showed CDI-45205 had excellent antiviral activity against the U.K. variant, with an EC50 of 1.9 uM (remdesivir EC50 0.6 uM; PF-00835231 EC50 >100 uM) and against the South African variant, with an EC50 of 2.5 uM (remdesivir EC50 0.8 uM; PF-00835231 EC50 >100 uM) in the absence of a P-glycoprotein efflux inhibitor.
In mouse and rat pharmacokinetic studies, CDI-45205 showed good bioavailability, and also no cytotoxicity against a variety of human cell lines.
Additionally, a proof-of-concept animal study demonstrated that daily injection of CDI-45205 exhibited favorable in vivo efficacy in MERS-CoV-infected mice.
Now read: Cocrystal Pharma EPS in-line